Southeast Asian stem cell leader, Medeze, has announced a voluntary conditional cash partial offer to acquire a 10% stake in Singapore-listed Cordlife Group Limited.
The offer, priced at S$0.25 per share, represents a 61.3% premium over Cordlife’s last traded price on 9 May 2025.
This strategic move marks Medeze’s entry into the Singapore market, aiming to explore long-term collaborations with Cordlife.
Medeze, through its subsidiary Medeze Treasury Pte Ltd, seeks to acquire 25,630,774 shares of Cordlife, a company known for its cord blood banking services.
The offer is contingent upon receiving valid acceptances for the full 10% stake. Medeze views this as an opportunity to enhance its market presence and explore synergies with Cordlife, potentially offering complementary services to each other’s customers.
The offer provides Cordlife shareholders with a chance to exit at a premium, especially considering the shares have been thinly traded in recent years.
Medeze’s CEO, Dr Veerapol Khemarangsan, emphasised the company’s commitment to creating long-term value and fostering constructive partnerships with Cordlife’s existing shareholders and management.
Medeze, recognised as the Southeast Asia Stem Cell Banking Company of the Year by Frost & Sullivan, has seen significant growth, with revenues reaching $24.3m (THB 874.3m). The company plans to leverage its expertise and resources to drive sustainable value creation for both Medeze and Cordlife, potentially expanding their services internationally.
“`
